The use of lncRNAs as molecular biomarkers emerged with the characterization of the long noncoding RNA PCA3 (prostate cancer antigen 3) and the finding of its upregulated expression in prostate cancer patients [134]. The gene discussed is PCA3; the disease is prostate carcinoma.